Symbols

LIXT

Lixte Biotechnology·NASDAQ

--(--)

7.60 / 10

Outperform

Analyst coverage is absent (ana_eval ‑1). Fund‑flow analysis rates 7.6/10 (good), with positive inflow ratios across all investor sizes (≈0.5‑0.6) and upward trends. Strong liquidity and buying pressure offset the lack of analyst guidance, supporting a bullish short‑term outlook.

Fund Flow Rating

What is the analyst consensus for LIXT?

LIXT holds a Neutral analyst rating, with 0% of experts assigning a Hold grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 7.60/10 (Outperform).